Homology Medicines
2015
FOUNDED
PUBLIC
STATUS
101-200
EMPLOYEES
FIXX
STOCK SYMBOL
$20.05
SHARE PRICE
(As of Friday Closing)
Description
Homology Medicines Inc is an US based is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 45 Wiggins Avenue
- Bedford, MA 01730
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Homology Medicines’s full profile, request a free trial.
Homology Medicines Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $15.07 - $31.80 | $874M | $20.48 | -$1.91 | 278K | 43.6M |
Homology Medicines Financials Summary
|
In Thousands,
USD |
TTM
31-Mar-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 826,207 | 708,747 | ||
| Revenue | 3,131 | 3,684 | 0 | 0 |
| EBITDA | (73,350) | (60,275) | (29,849) | (7,831) |
| Net Income | (70,543) | (57,215) | (29,991) | (8,047) |
| Total Assets | 233,026 | 259,094 | 137,530 | 14,219 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Homology Medicines Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Homology Medicines‘s full profile, request access.
Request full access to PitchBookHomology Medicines Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Homology Medicines‘s full profile, request access.
Request full access to PitchBookHomology Medicines Competitors (40)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regenxbio | Formerly VC-backed | Rockville, MD | 000 | 00000 | 00000000000 | 00000 |
| 0000 000000 | Formerly VC-backed | San Diego, CA | 00 | 00000 | 000000000 | 00000 |
| 000000000 00000000 | Formerly VC-backed | Montreal, Canada | 00 | 00000 | 000000&0 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Richmond, CA | 000 | 000.00 | 00000000 | 000.00 |
| 000 00000000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
Homology Medicines Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Homology Medicines‘s full profile, request access.
Request full access to PitchBookHomology Medicines Executive Team (9)
1 Former Executive
You’re viewing 5 of 9 executives. Get the full list »Homology Medicines Board Members (11)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Arthur Tzianabos Ph.D | Homology Medicines | President, Board Member & Chief Executive Officer | 000 0000 | |
| Cameron Wheeler Ph.D | Deerfield Management | Board Member | 000 0000 | |
| Jason Ruth Ph.D | 5AM Ventures | Board Observer | 000 0000 | |
| Kush Parmar Ph.D | 5AM Ventures | Board Member | 000 0000 | |
| Mahendra Shah Ph.D | Vivo Capital | Board Member | 000 0000 |
1 Former Board Member
You’re viewing 5 of 11 board members. Get the full list »